EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human ACE2 Gene Replacement Mice Support SARS-CoV-2 Viral Replication and Nonlethal Disease Progression

Joshua M Thiede iD, Jenna K Dick iD, Nicholas N Jarjour iD, Venkatramana D Krishna iD, Lily Qian iD, Jules Sangala iD, Kellie Benzow, Kul Karanjeet, Shine Chin, Orion Rainwater iD, Maxim C-J Cheeran iD, Kristin A Hogquist und 4 weitere

ImmunoHorizons · 2024

DOI: 10.4049/immunohorizons.2400030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoHorizons, 2024. Verfasst von Joshua M Thiede und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunology, University of Minnesota Medical School, Minneapolis, MN. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, COVID-19, Virus Replication. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many mouse models of SARS-CoV-2 infection involve expression of the human ACE2 protein, the entry receptor for SARS-CoV-2 Spike protein, in mouse tissues. However, most of these models suffer from nonphysiological regulation of ACE2 expression, which can lead to atypically severe infections and aberrant sites of viral replication. In this report, we developed and characterized an ACE2 gene replacement (ACE2-GR) mouse strain in which the mouse Ace2 genomic locus was replaced by the entire human ACE2 gene locus, and we investigated the ability of these animals to respond to SARS-CoV-2 infection. We show that ACE2-GR mice support SARS-CoV-2 viral replication, but, in stark contrast to the widely used K18-hACE2 transgenic model, this infection leads to a mild disease with no detectable involvement of the CNS. Thus, ACE2-GR mice provide a novel, to our knowledge, model to explore immune responses and long-term consequences of SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2SARS-CoV-2COVID-19Virus ReplicationDisease Models, AnimalDisease ProgressionAnimalsMiceHumansMice, TransgenicSpike Glycoprotein, CoronavirusMice, Inbred C57BL

Substanzen

Angiotensin-Converting Enzyme 2ACE2 protein, humanAce2 protein, mouseSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Center for Immunology, University of Minnesota Medical School, Minneapolis, MN.
  • Department of Medicine, University of Minnesota Medical School, Minneapolis, MN.
  • Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN.
  • Department of Veterinary Population Medicine, University of Minnesota College of Veterinary Medicine, St. Paul, MN.

ORCID-Profile: Joshua M Thiede, Jenna K Dick, Nicholas N Jarjour, Venkatramana D Krishna, Lily Qian, Jules Sangala, Orion Rainwater, Maxim C-J Cheeran, Stephen C Jameson, Geoffrey T Hart

Förderung

  • NIAID NIH HHS

Zitieren

APA

Thiede, J. M., Dick, J. K., Jarjour, N. N., Krishna, V. D., Qian, L., Sangala, J., Benzow, K., Karanjeet, K., Chin, S., Rainwater, O., Cheeran, M. C., Hogquist, K. A., Jameson, S. C., Hart, G. T., Bold, T. D., & Koob, M. D. (2024). Human ACE2 Gene Replacement Mice Support SARS-CoV-2 Viral Replication and Nonlethal Disease Progression. ImmunoHorizons. https://doi.org/10.4049/immunohorizons.2400030

Vancouver

Thiede JM, Dick JK, Jarjour NN, Krishna VD, Qian L, Sangala J, et al. Human ACE2 Gene Replacement Mice Support SARS-CoV-2 Viral Replication and Nonlethal Disease Progression. ImmunoHorizons. 2024. doi:10.4049/immunohorizons.2400030

BibTeX
@article{Thiede2024,
  author = {Thiede, Joshua M and Dick, Jenna K and Jarjour, Nicholas N and Krishna, Venkatramana D and Qian, Lily and Sangala, Jules and Benzow, Kellie and Karanjeet, Kul and Chin, Shine and Rainwater, Orion and Cheeran, Maxim C-J and Hogquist, Kristin A and Jameson, Stephen C and Hart, Geoffrey T and Bold, Tyler D and Koob, Michael D},
  title = {Human ACE2 Gene Replacement Mice Support SARS-CoV-2 Viral Replication and Nonlethal Disease Progression},
  journal = {ImmunoHorizons},
  year = {2024},
  doi = {10.4049/immunohorizons.2400030}
}
Kostenlos starten →